Review
Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma
Affiliations
- PMID: 12901151
Item in Clipboard
Review
Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma
Curr Hematol Rep.
2003 Jan.
Abstract
Monoclonal antibodies have been used as a therapeutic option for patients with lymphoma for less than 5 years, but they have already changed our perception of how to treat these patients. In this review, the use of different types of monoclonal antibodies in the treatment of patients with diffuse large B-cell lymphoma is analyzed, particularly the combination of rituximab with chemotherapy as a first-line therapeutic option. The putative role of other monoclonal antibodies is discussed.
Similar articles
-
[Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].Ai Zheng. 2005 Dec;24(12):1498-502. Ai Zheng. 2005. PMID: 16351800 Chinese.
-
Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.Br J Haematol. 2008 Dec;143(5):672-80. doi: 10.1111/j.1365-2141.2008.07390.x. Epub 2008 Oct 20. Br J Haematol. 2008. PMID: 18950459
-
Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.Ann Hematol. 2006 Apr;85(4):257-62. doi: 10.1007/s00277-005-0060-6. Epub 2006 Jan 17. Ann Hematol. 2006. PMID: 16416337
-
Diffuse large B-cell lymphoma.Clin Adv Hematol Oncol. 2005 Nov;3(11):suppl 4-5. Clin Adv Hematol Oncol. 2005. PMID: 16491628 Review. No abstract available.
-
Standard treatment of advanced-stage diffuse large B-cell lymphoma.Semin Hematol. 2006 Oct;43(4):213-20. doi: 10.1053/j.seminhematol.2006.07.004. Semin Hematol. 2006. PMID: 17027655 Review.
Cited by
-
RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop.Crit Rev Oncog. 2014;19(6):431-45. doi: 10.1615/critrevoncog.2014011929. Crit Rev Oncog. 2014. PMID: 25597353 Free PMC article. Review.
-
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.Cancer Immunol Immunother. 2022 May;71(5):1017-1031. doi: 10.1007/s00262-021-03054-8. Epub 2021 Sep 20. Cancer Immunol Immunother. 2022. PMID: 34545416 Free PMC article.
-
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.Cancer Immunol Immunother. 2022 Oct;71(10):2497-2509. doi: 10.1007/s00262-022-03177-6. Epub 2022 Mar 9. Cancer Immunol Immunother. 2022. PMID: 35262781 Free PMC article.